Evidence map›Paper›PMID 29892547›Full record

ArticleLeukemia research reports2018

1,25-OH

Maximilian Pistor, Lisa Schrewe, Steffen Haupeltshofer, Andrei Miclea, Simon Faissner, Andrew Chan, Robert Hoepner

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia research reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Maximilian PistorDepartment of Neurology, Neuroimmunology Lab, St. Josef Hospital, Ruhr University Bochum, Universitätsstrasse 150, 44801 Bochum, Germany.
Lisa SchreweDepartment of Neurology, Inselspital, University Hospital Bern, Switzerland.
Steffen HaupeltshoferDepartment of Neurology, Neuroimmunology Lab, St. Josef Hospital, Ruhr University Bochum, Universitätsstrasse 150, 44801 Bochum, Germany.
Andrei MicleaMedical Faculty, Ruhr-University Bochum, Germany.
Simon FaissnerDepartment of Neurology, St. Josef Hospital, Ruhr University Bochum, Germany.
Andrew ChanDepartment of Neurology, Inselspital, University Hospital Bern, Switzerland.
Robert HoepnerDepartment of Neurology, Inselspital, University Hospital Bern, Switzerland.
St. Josef-Hospital · DEUniversity Hospital of Bern · CHRuhr University Bochum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In acute lymphoblastic leukemia (ALL), steroid resistance and hypovitaminosis D are both associated with a poor prognosis. We show that methylprednisolone, calcitriol and the AKT-inhibitor MK-2206 have a synergistic effect on the apoptosis of steroid resistant T-ALL cells. Compared to methylprednisolone monotherapy, calcitriol increases methylprednisolone induced apoptosis dose-dependently (1.37-1.92-fold; p < 0.05). Pre-incubation with calcitriol increases the apoptotic effect of MK-2206 even further (3.6-fold; p < 0.05). It also potentiates synergism between MK-2206 and methylprednisolone (vehicle control 38% vs. calcitriol 58%, p < 0.01). The combination of calcitriol and AKT inhibition should be investigated further as treatment options for steroid resistance in T-ALL.

Indexed as

CalcitriolJurkatMK-2206RuxolitinibSteroid resistance

Identifiers

PMID29892547
PMCPMC5993358
OpenAlexW2793912836

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.